SYT-510

Last updated
SYT-510
Clinical data
Other namesSYT510
Routes of
administration 		Oral [1]
Drug class Endocannabinoid reuptake inhibitor [2]

SYT-510 is an endocannabinoid reuptake inhibitor, or "selective endocannabinoid reuptake inhibitor" ("SERI"), which is under development for the treatment of anxiety disorders, mood disorders, and traumatic stress disorders. [2] [1] [3] [4] It is said to mildly and selectively increase levels of endocannabinoids like anandamide via inhibition of a newly identified biological target. [4] [2] As of January 2024, the drug is in the preclinical stage of development or is entering phase 1 clinical trials for the preceding indications. [2] [1] [4] [3] It is under development by a pharmaceutical company called Synendos Therapeutics. [2] [1] [3]

References

  1. 1 2 3 4 "Delving into the Latest Updates on SYT-510 with Synapse". Synapse. 4 August 2024. Retrieved 15 August 2024.
  2. 1 2 3 4 5 "SYT 510". AdisInsight. 22 January 2024. Retrieved 15 August 2024.
  3. 1 2 3 Gertsch J, Chicca A (July 2024). "CNS Drug Discovery in Academia: Where Basic Research Meets Innovation". ChemBioChem e202400397. doi: 10.1002/cbic.202400397 . PMID   38958639. Five years after incorporation, Synendos Therapeutics has completed non-clinical development of the [selective endocannabinoid reuptake inhibitor (SERI)] drug candidate SYT-510 and has initiated Phase 1 clinical development in healthy volunteers, marking the significant transition into a clinical stage biotech company. The mission of Synendos is to develop breakthrough safe and effective therapies for neurological and neuropsychiatric disorders through modulation of the [endocannabinoid system (ECS)] with SERIs to enable restoration of the natural functioning of the brain.
  4. 1 2 3 Therapeutics, Synendos (18 January 2024). "Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510". PR Newswire. Retrieved 15 August 2024.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.